Alba J R, Basterra J, Ferrer J C, Santonja F, Zapater E
Department of ENT,University General Hospital,Valencia Medical School,Spain.
Department of Endocrinology,University General Hospital,Valencia Medical School,Spain.
J Laryngol Otol. 2016 May;130(5):478-81. doi: 10.1017/S0022215116000967. Epub 2016 Mar 15.
Hypothyroidism is a common complication when radiotherapy is part of the treatment for head and neck tumours. This study aimed to show the incidence of hypothyroidism and possible risk factors in these patients.
Factors related to the population, tumour, treatment and occurrence of hypothyroidism were analysed in 241 patients diagnosed with head and neck carcinoma.
Approximately 53 per cent of patients were diagnosed with radiation-induced hypothyroidism. Its occurrence was related to: tumour location, laryngeal surgery type, neck dissection type, post-operative complications, cervical radiotherapy and radiotherapy unit type (linear particle accelerator or telecobalt therapy technology).
Control of thyroid function should be standardised for several years after treatment, particularly in patients with risk factors, such as those treated with telecobalt therapy, those with post-operative complications and for whom the thyroid parenchyma is included in the irradiated area (laryngeal or pharyngeal location and bilateral cervical radiation).
甲状腺功能减退是头颈部肿瘤放射治疗常见的并发症。本研究旨在明确这些患者甲状腺功能减退的发生率及可能的危险因素。
对241例头颈部癌患者分析了与人群、肿瘤、治疗及甲状腺功能减退发生相关的因素。
约53%的患者被诊断为放射性甲状腺功能减退。其发生与以下因素有关:肿瘤位置、喉部手术类型、颈部清扫类型、术后并发症、颈部放疗及放疗设备类型(直线加速器或远距离钴治疗技术)。
治疗后数年应规范甲状腺功能监测,尤其是有危险因素的患者,如接受远距离钴治疗的患者、有术后并发症的患者以及甲状腺实质位于照射区域内的患者(喉部或咽部位置及双侧颈部放疗)。